XML 21 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Income - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Net sales $ 10,431 $ 10,765
Cost of sales 9,760 9,488
Research and development expenses 200 204
Selling, general and administrative expenses 366 442
Amortization of intangibles 76 81
Restructuring and asset related charges - net 208 45
Equity in earnings (losses) of nonconsolidated affiliates (20) 17
Sundry income (expense) - net 13 61
Interest income 28 65
Interest expense and amortization of debt discount 216 199
Income (loss) before income taxes (374) 449
Credit for income taxes (84) (89)
Net income (loss) (290) 538
Net income attributable to noncontrolling interests 17 22
Net income (loss) available for The Dow Chemical Company common stockholder (307) 516
The Dow Chemical Company    
Net sales 10,431 10,765
Cost of sales 9,759 9,487
Research and development expenses 200 204
Selling, general and administrative expenses 366 442
Amortization of intangibles 76 81
Restructuring and asset related charges - net 208 45
Equity in earnings (losses) of nonconsolidated affiliates (20) 17
Sundry income (expense) - net 13 61
Interest income 29 69
Interest expense and amortization of debt discount 216 199
Income (loss) before income taxes (372) 454
Credit for income taxes (84) (89)
Net income (loss) (288) 543
Net income attributable to noncontrolling interests 17 22
Net income (loss) available for The Dow Chemical Company common stockholder $ (305) $ 521